HOME >> BIOLOGY >> NEWS
Expanding the genetic code--TSRI scientists synthesize 21-amino-acid bacterium

Scientists at The Scripps Research Institute (TSRI) report in an upcoming article in the Journal of the American Chemical Society their synthesis of a form of the bacterium Escherichia coli with a genetic code that uses 21 basic amino acid building blocks to synthesize proteins--instead of the 20 found in nature.

This is the first time that anyone has created a completely autonomous organism that uses 21 amino acids and has the metabolic machinery to build those amino acids.

"We now have the opportunity to ask whether a 21-amino acid form of life has an evolutionary advantage over life with 20 amino acids," says the report's lead author Peter Schultz, Ph.D., TSRI professor of chemistry and Scripps Family Chair of TSRI's Skaggs Institute of Chemical Biology.

"We have effectively removed a billion-year constraint on our ability to manipulate the structure and function of proteins," he says.

In addition to demonstrating that life is possible with additional amino acids, the work is of great relevance to science and medicine because it enables scientists to chemically manipulate the proteins that an organism produces within the organism itself. This gives scientists a powerful tool for research, from determining molecular structures to creating molecular medicines.

Why Expand the Genetic Code?

Life as we know it is composed, at the molecular level, of the same basic building blocks for instance, all life forms on Earth use the same four nucleotides to make DNA. And almost without exception, all known forms of life use the same common 20 amino acids--and only those 20--to make proteins.

"The question is," asks Schultz, "why did life stop with 20 and why these 20?"

While the answer to that question may be elusive, the 20-amino acid barrier is far from absolute. In some rare instances, in fact, certain organisms have evolved the ability to use the unusual amino acids selenocysteine and pyrrolysine--sli
'"/>

Contact: Jason Bardi
jasonb@scripps.edu
858-784-9254
Scripps Research Institute
14-Jan-2003


Page: 1 2 3 4

Related biology news :

1. Expanding the genetic code: the worlds first truly unnatural organism
2. Expanding lifes alphabet
3. Researchers determine genetic cause of Timothy syndrome
4. Rare childhood genetic syndrome identified
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Scientists decipher genetic code of biothreat pathogen
7. Chemical genetics identifies SARS inhibitors
8. 22nd amino acid synthesized and added to genetic code of e. coli bacteria
9. The impact of genetic variations on the treatment of early rheumatoid arthritis
10. Adaptive changes in the genome may provide insight into the genetics of complex disease
11. New genetic hypothesis for the cause of autism

Post Your Comments:
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: